Schultheiss H P
Medizinische Klinik, Universität München, Bundesrepublik Deutschland.
Wien Klin Wochenschr. 1988 Dec 16;100(24):779-86.
The diagnosis of "viral myocarditis" remains uncertain in most cases, despite varied efforts to obtain diagnostic criteria and techniques. The combination of virological, histological and immunohistological data may offer an opportunity to improve diagnosis. The pathophysiological processes which are involved in the transition from myocarditis into dilated cardiomyopathy are still unclear. A variety of new data point out that viral infection induces a loss of self-tolerance and subsequent autoaggression towards myocardial structures. The management of viral myocarditis remains problematic and a specific form of therapy still does not exist. Studies on immune suppressive therapy are contradictory. Moreover, in these studies the diagnostic criteria were non-uniform and the number of patients was low. Nevertheless, immune suppressive therapy can be very effective in individual cases. But until now, a clear decision cannot be made on the selection of those patients who would respond favourably to immune suppressive therapy. Only controlled studies which consider the aetiology, the grade of clinical severity, the duration of clinical symptoms, the degree of cellular infiltration, and the histological alterations may answer the questions concerning the benefit of immune suppressive therapy for viral myocarditis and its sequelae. Until these studies are available, the general implementation of immune suppressive therapy in viral heart disease should not be recommended, especially in view of the incidence of side effects.
尽管人们为获取诊断标准和技术付出了种种努力,但在大多数情况下,“病毒性心肌炎”的诊断仍不明确。病毒学、组织学和免疫组织学数据的结合可能为改善诊断提供契机。从心肌炎转变为扩张型心肌病所涉及的病理生理过程仍不清楚。各种新数据表明,病毒感染会导致自身耐受性丧失,并随之对心肌结构产生自身攻击。病毒性心肌炎的治疗仍然存在问题,目前仍不存在特定的治疗形式。关于免疫抑制疗法的研究结果相互矛盾。此外,在这些研究中,诊断标准并不统一,且患者数量较少。然而,免疫抑制疗法在个别病例中可能非常有效。但到目前为止,对于哪些患者会对免疫抑制疗法产生良好反应,还无法做出明确的选择。只有考虑病因、临床严重程度分级、临床症状持续时间、细胞浸润程度和组织学改变的对照研究,才能回答免疫抑制疗法对病毒性心肌炎及其后遗症是否有益的问题。在这些研究结果出来之前,不建议在病毒性心脏病中普遍实施免疫抑制疗法,尤其是考虑到副作用的发生率。